Facebook Twitter RSS Feed

You are here

Structural Heart

 - TAVR

WASHIINGTON, D.C.—Transcatheter aortic valve replacement (TAVR) added more than two years to the life of inoperable patients with severe aortic stenosis, according to five-year results of the PARTNER I trial presented Sept. 13 at the Transcatheter Cardiovascular Therapeutics scientific session. The device also showed good durability, researchers said.

 - CoreValve

A meta-analysis of predictors of permanent pacemaker implantation after transcatheter aortic valve replacement (TAVR) reinforced findings that patients treated with the CoreValve device were at increased risk compared with patients receiving the Sapien device. The predictors may help physicians avoid atrioventricular block-related complications, regardless of device type.

 - Heart

Patients with baseline stenosis or small surgical valves who undergo transcatheter aortic valve-in-valve implantation for failed bioprosthetic devices have lower survival rates than the overall patient population, according to a study published in the July 9 issue of JAMA.

 - TAVR

Limiting access to transcatheter aortic valve replacement (TAVR) therapy to inoperable patients suitable for only a transfemoral approach reduced the number of patients who received care, particularly women, in a study that evaluated the effect of the national coverage determination (NCD). 

 - teen

Children’s hospital physicians cautioned surgeons against implanting the Mitroflow bioprosthetic aortic valve in young patients who undergo aortic valve replacement and recommended vigilant surveillance of those who already have the device.

 

More Stories

FDA OKs CoreValve for high-risk patients

The FDA approved the CoreValve device for transcatheter aortic valve replacement (TAVR) in high-risk patients with severe aortic stenosis without a review from an expert panel. While the favorable decision was expected, the road to it developed a few potholes.

Tool IDs patients with poor outcomes after TAVR

A model that includes quality of life (QoL) in its assessment predicted with moderate discrimination patients who likely would have poor outcomes after undergoing transcatheter aortic valve replacement (TAVR), according to results published online May 23 in Circulation.

TAVR triumphs

This week, two titans in transcatheter aortic valve replacement (TAVR) settled a feud over patents. One beneficiary of that agreement may be TAVR itself.

TAVR détente: Edwards, Medtronic settle patent dispute

Edwards Lifesciences and Medtronic reached a cross-license settlement over transcatheter aortic valve replacement (TAVR) devices with provisions that should put their patent dispute to rest.

CMS supports coverage for transcatheter mitral devices

The Centers for Medicare & Medicaid Services (CMS) is proposing to cover transcatheter mitral valve repair, but only if certain conditions are met.

AATS: No signs of risk creep with TAVR

Fears that physicians may be treating patients who are suitable candidates for standard care with less invasive transcatheter aortic valve replacement (TAVR) may be allayed, based on results presented April 28 at the American Association of Thoracic Surgery meeting in Toronto.

AATS: Complex cardiac surgeries may require continued training

Cardiac surgeons may benefit from continuous training if they perform complex or rare procedures, according to an abstract presented April 28 at the American Association for Thoracic Surgery meeting in Toronto.

FDA approves valve treated to prevent calcification

The FDA approved a bioprosthetic heart valve that is treated to improve durability.

Court grants delay on CoreValve injunction

Does CoreValve have a pulse? A federal court of appeals granted Medtronic’s request to delay implementation of a preliminary injunction that would limit the sale of the device in the U.S.

Judge limits sale of CoreValve but grants delay

A federal court called for a preliminary injunction limiting the sale of the CoreValve device in the U.S. but granted a reprieve before the injunction is scheduled to go into effect.

Technically inoperable patients fare best after TAVR

Transcatheter aortic valve replacement (TAVR) patients who are inoperable because of technical reasons have better outcomes than TAVR patients who are clinically inoperable, a finding that could help identify patients likely to reap the greatest benefit from the procedure.

European office revokes patent on TAVR valve

In the latest in a battle between the titans in transcatheter aortic valve replacement (TAVR), the European Patent Office invalidated a patent at the heart of Edwards Lifesciences’ infringement case against Medtronic.

Valvular heart disease guidelines add TAVR, updates

Recently released practice guidelines for treating patients with valvular heart disease forged new ground on several fronts. For the first time, they included recommendations for transcatheter aortic valve replacement (TAVR) as well as a new classification system.

Aortic stenosis: Lifelong learning in the 21st century

Transcatheter aortic valve replacement (TAVR) for eligible patients with severe aortic stenosis holds great promise but much still needs to be learned. The American College of Cardiology (ACC) is piloting an initiative that is designed to help valve centers in the U.S. improve quality and achieve good outcomes.

TAVR offers only modest benefits in some realms

Transcatheter aortic valve replacement (TAVR) may confer only modest psychological and general health benefits, according to a systematic review published Feb. 18 in the Annals of Internal Medicine

Newborn pulse ox screening may help detect heart defects earlier

About 30 percent of infants born with critical congenital heart disease have their conditions detected more than three days after birth, and the use of a universal screening tool based on pulse oximetry could result in earlier detection, according to a study published online Feb. 3 in JAMA Pediatrics.

Findings challenge donor heart allocation process

Outcomes in patients waiting for heart transplants may vary according to the length of waiting list time, findings in a study published online Jan. 29 in the Journal of the American College of Cardiology showed.

TAVR insights

Is it possible to score two home runs with a single hit? The Society of Thoracic Surgeons achieved that this week during their annual meeting in Orlando, Fla.

Inhospital mortality leaps after TAVR commercialization

Outcomes for patients undergoing traditional surgical and less invasive treatments for aortic stenosis have improved over time, but a recent uptick in the inhospital mortality rate with transcatheter aortic valve replacement (TAVR) may raise concerns.

 

Edwards wins latest TAVR patent tussle

Déjà vu? A federal jury determined that Medtronic’s CoreValve transcatheter aortic valve replacement (TAVR) device infringed on a patent owned by Edwards Lifesciences, a finding Medtronic indicated it would appeal. The jury awarded Edwards Lifesciences $394 million in damages.